Pancreas carcinoma antigen fused to invariant chain elicits t-cell response and tumor growth inhibition

Pancreas

Volumn 37, Issue 3, 2008, Pages 321-327

  Nagaraj, Srinivas ^a,b   Neumann, Juergen ^a   Winzen, Bettina ^a   Frank, Susanne ^a   Ziske, Carsten ^a   Sievers, Elisabeth ^a   Koch, Norbert ^a   Schmidt Wolf, Ingo G H ^a,c  

^a UNIVERSITY OF BONN   (Germany)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

C2GnT epitopes; Dendritic cells; Invariant chain; MHC class II; Pancreatic cancer

Indexed keywords

2BETA 1,6 N ACETYLGLUCOSAMINYLTRANSFERASE; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; BETA 1,3 GALACTOSYL O GLYCOSYL GLYCOPROTEIN BETA 1,6 ACETYLGLUCOSAMINYL TRANSFERASE; BETA-1,3-GALACTOSYL-O-GLYCOSYL-GLYCOPROTEIN BETA-1,6-ACETYLGLUCOSAMINYL TRANSFERASE; CANCER VACCINE; HLA ANTIGEN CLASS 2; HYBRID PROTEIN; N ACETYLGLUCOSAMINYLTRANSFERASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CELL STRAIN COS1; CERCOPITHECUS; GENETICS; IMMUNOLOGY; INVARIANT CHAIN; PANCREAS TUMOR; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; MALE; MICE; MICE, INBRED C57BL; N-ACETYLGLUCOSAMINYLTRANSFERASES; PANCREATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 58149359310     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318166722e7     Document Type: Article

References (29)

1. Armstrong AC, Eaton D, Ewing JC. Science, medicine, and the future: cellular immunotherapy for cancer. BMJ. 2001;323:1289-1293.
2. Armstrong AC, Eaton D, Ewing JC. Cellular vaccine therapy for cancer. Expert Rev Vaccines. 2002;1:303-316.
3. Beum PV, Singh J, Burdick M, et al. Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes. J Biol Chem. 1999;274:24641-24648.
4. Mukasa R, Homma T, Ohtsuki T, et al. Core 2-containing O-glycans on CD43 are referentially expressed in the memory subset of human CD4 T cells. Int Immunol. 1999;11:259-268.
5. Nakayama J, Shimizu F, Katsuyama T. Glycosyltransferase genes as tumor marker. Rinsho Byori Suppl. 2002;123:142-148.
6. Panicot L, Mas E, Pasqualini E, et al. The formation of the oncofetal J28 glycotope involves core-2 beta6-N-acetylglucosaminyltransferase and alpha3/4-fucosyltransferase activities. Glycobiology. 1999;9: 935-946.
7. Koch N, van Driel IR, Gleeson PA. Hijacking a chaperone: manipulation of the MHC class II presentation pathway. Immunol Today. 2000;21: 546-550.
8. Schmidt T, Ziske C, Marten A, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003;63: 8962-8967.
9. Koch S, Schultz A, Koch N. The production of recombinant HLA-DR beta and invariant chain polypeptides by cDNA expression in E. coli. J Immunol Methods. 1987;103:211-220.
10. Pesando JM, Graf L. Differential expression of HLA-DR, -DQ, and -DP antigens on malignant B cells. J Immunol. 1986;136:4311-4318.
11. Wraight CJ, van Endert P, Moller P, et al. Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem. 1990;265:5787-5792.
12. Adams TE, Bodmer JG, Bodmer WF. Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens. Immunology. 1983;50:613-624.
13. Ziske C, Marten A, Schottker B, et al. Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Mol Ther. 2001;3: 54-60.
14. Nagaraj S, Ziske C, Schmidt-Wolf IGH. Dendritic cell, the immunotherapeutic cell for cancer. Indian J Med Res. 2004;119:133-138.
15. Chaux P, Vantomme V, Stroobant V, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999;189:767-778.
16. Fujii S, Senju S, Chen YZ, et al. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol. 1998;59:607-614.
17. Nakano N, Rooke R, Benoist C, et al. Positive selection of T cells induced by viral delivery of neopeptides to the thymus. Science. 1997; 275:678-683.
18. Sanderson F, Kleijmeer MJ, Kelly A, et al. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science. 1994;266:1566-1569.
19. Wang RF, Wang X, Atwood AC et al. Cloning genes encoding MHC class IIYrestricted antigens: mutated CDC27 as a tumor antigen. Science. 1999;284:1351-1354.
20. Siebenkotten IM, Carstens C, Koch N. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes. J Immunol. 1998;160:3355-3362.
21. van Bergen J, Schoenberger SP, Verreck F, et al. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci U S A. 1997;94:7499-7502.
22. Donnelly JJ, Wahren B, Liu MA. DNAvaccines: progress and challenges. J Immunol. 2005;175:633-639.
23. Marshall DJ, San Mateo LR, Rudnick KA, et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother. 2005;54:1082-1094.
24. Pavlenko M, Leder C, Pisa P. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev Vaccines. 2005;4:315-327.
25. Fong CL, Mok CL, Hui KM. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther. 2005;15:15.
26. Jia ZC, Zou LY, Ni B, et al. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta. Cancer Immunol Immunother. 2005;54:446-452.
27. Yamano T, Kaneda Y, Huang S, et al. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther. 2005;19:19.
28. Zhou H, Luo Y, Lo JF, et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A. 2005;102:10846-10851.
29. Qin H, Zhou C, Wang D, et al. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol Lett. 2005;99:85-93.